WallStSmart
MGX

Metagenomi, Inc. Common Stock

NASDAQ: MGX · HEALTHCARE · BIOTECHNOLOGY

$1.35
+0.00% today

Updated 2026-06-03

Market cap
$48.19M
P/E ratio
P/S ratio
2.16x
EPS (TTM)
$-2.29
Dividend yield
52W range
$1 – $4
Volume
0.2M

Metagenomi, Inc. Common Stock (MGX) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20212022202320242025
Total assets$141.99M$414.49M$364.84M$324.60M$221.10M
Cash & equivalents$39.30M$184.44M$140.60M$27.39M$41.72M
Current assets$108.92M$366.90M$278.27M$257.96M$165.54M
Total liabilities$174.54M$488.91M$149.67M$89.74M$62.51M
Current liabilities$25.17M$48.54M$68.86M$37.31M$22.93M
Long-term debt$30.28M
Shareholder equity$-32.54M$-74.43M$215.17M$234.86M$158.60M
Retained earnings$-33.10M$-76.69M$-144.94M$-223.00M$-310.87M
Accounts receivable$490000.00$1.27M$2.45M$1.26M$305000.00
Inventory
Goodwill

Frequently asked questions

What is Metagenomi, Inc. Common Stock's revenue?

Metagenomi, Inc. Common Stock's trailing twelve-month revenue is $22.33M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is MGX?

In its most recent fiscal year, MGX ran a gross margin of 78.91%, an operating margin of -380.85%, and a net margin of -348.54%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does MGX generate?

MGX produced $-89.47M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MGX's balance sheet healthy?

MGX holds $41.72M in cash and equivalents against — in long-term debt, on $158.60M of shareholder equity. That debt is best read against the cash flow the business throws off each year.